ValiRx plc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| VAL.L | BDRX | NFX.L | APVO | NIKI | TOVX | |
|---|---|---|---|---|---|---|
| Market cap | 2.11M | 1.41M | 2.87M | 2.90M | 5.27M | 8.72M |
| P/E (TTM) | — | 0.0 | — | 0.0 | — | 0.3 |
| Forward P/E | 0.0 | — | — | -0.1 | — | -1.0 |
| Price/book | 0.4 | 0.0 | 1.1 | 0.3 | 0.1 | 0.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −27.66% | −98.73% | −74.68% | −94.72% | −87.43% | −40.00% |
| Today | 0.00% | −4.61% | +10.00% | +0.74% | −3.98% | +4.40% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All VAL.L news ›ValiRx highlights 5.55% Ambrose Healthcare stake following €161 million AM-Pharma acquisition
ValiRx Plc (AIM: VAL) has highlighted its indirect 5.55% shareholding in Ambrose Healthcare following the private pharmaceutical company’s agreement to acquire AM-Pharma for up to €161 million, drawing investor attention to the potential…
REG - ValiRx PLC - Update on Ambrose Healthcare shareholding
("ValiRx" or the "Company") London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, notes the movement in the Company's share price on 20 October 2026 following the…
EARNINGS AND TRADING: ValiRx profit slides; Ukrproduct loss narrows
The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: ---------- ValiRx PLC - London-based life science company - Reports... Biotechnology & Medical Research…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com1
- share-talk.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.